A novel indole compound MA-35 attenuates renal fibrosis by inhibiting both TNF-α and TGF-β1 pathways

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Shima, Hisato ^a   Sasaki, Kensuke ^b   Suzuki, Takehiro ^a,c   Mukawa, Chikahisa ^c   Obara, Ten ^d   Oba, Yuki ^a   Matsuo, Akihiro ^a   Kobayashi, Takayasu ^c   Mishima, Eikan ^a   Watanabe, Shun ^a   Akiyama, Yasutoshi ^a   Kikuchi, Koichi ^a   Matsuhashi, Tetsuro ^a   Oikawa, Yoshitsugu ^a   Nanto, Fumika ^a,c   Akiyama, Yukako ^a   Ho, Hsin Jung ^a,c   Suzuki, Chitose ^a   Saigusa, Daisuke ^c   Masamune, Atsushi ^a   Tomioka, Yoshihisa ^c   Masaki, Takao ^b   Ito, Sadayoshi ^a   Hayashi, Ken Ichiro ^e   Abe, Takaaki ^a,c   more..

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d INDIANA UNIVERSITY   (United States)

^e OKAYAMA UNIVERSITY OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; I KAPPA B KINASE; INDOLE DERIVATIVE; LIPOPOLYSACCHARIDE; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR;

ANIMAL; BIOLOGICAL MODEL; CELL LINE; DISEASE MODEL; DRUG EFFECT; EXTRACELLULAR MATRIX; FIBROSIS; HEPATITIS; HUMAN; KIDNEY DISEASE; MALE; METABOLISM; METHYLATION; MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FIBROSIS; HEPATITIS; HISTONES; HUMANS; I-KAPPA B KINASE; INDOLES; KIDNEY DISEASES; LIPOPOLYSACCHARIDES; MALE; METHYLATION; MICE; MODELS, BIOLOGICAL; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85019456719     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-01702-7     Document Type: Article

References (27)

1. Rockey, D. C., Bell, P. D. & Hill, J. A. Fibrosis-a common pathway to organ injury and failure. The New England journal of medicine 372, 1138-1149, doi:10.1056/NEJMra1300575 (2015).
2. Meldrum, K. K. et al. TNF-alpha neutralization ameliorates obstruction-induced renal fibrosis and dysfunction. American journal of physiology. Regulatory, integrative and comparative physiology 292, R1456-1464, doi:10.1152/ajpregu.00620.2005 (2007).
3. Neelisetty, S. et al. Renal fibrosis is not reduced by blocking transforming growth factor-beta signaling in matrix-producing interstitial cells. Kidney international 88, 503-514, doi:10.1038/ki.2015.51 (2015).
4. Yanagita, M. Inhibitors/antagonists of TGF-beta system in kidney fibrosis. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association 27, 3686-3691, doi:10.1093/ndt/gfs381 (2012).
5. Meng, X. M., Nikolic-Paterson, D. J. & Lan, H. Y. TGF-beta: the master regulator of fibrosis. Nature reviews. Nephrology 12, 325-338, doi:10.1038/nrneph.2016.48 (2016).
6. Yao, H. W. & Li, J. Epigenetic modifications in fibrotic diseases: implications for pathogenesis and pharmacological targets. The Journal of pharmacology and experimental therapeutics 352, 2-13, doi:10.1124/jpet.114.219816 (2015).
7. Imagawa, S. et al. A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 17, 1742-1744, doi:10.1096/fj.02-1134fje (2003).
8. Suzuki, T. et al. Mitochonic Acid 5 (MA-5), a Derivative of the Plant Hormone Indole-3-Acetic Acid, Improves Survival of Fibroblasts from Patients with Mitochondrial Diseases. The Tohoku journal of experimental medicine 236, 225-232, doi:10.1620/ tjem.236.225 (2015).
9. Suzuki, T. et al. Mitochonic Acid 5 Binds Mitochondria and Ameliorates Renal Tubular and Cardiac Myocyte Damage. Journal of the American Society of Nephrology: JASN 27, 1925-1932, doi:10.1681/asn.2015060623 (2016).
10. Flick, D. A. & Gifford, G. E. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. Journal of immunological methods 68, 167-175 (1984).
11. Zheng, Z. et al. Screening of an anti-inflammatory peptide from Hydrophis cyanocinctus and analysis of its activities and mechanism in DSS-induced acute colitis. Scientific reports 6, 25672, doi:10.1038/srep25672 (2016).
12. Fujita, T. et al. Hepatic stellate cells relay inflammation signaling from sinusoids to parenchyma in mouse models of immunemediated hepatitis. Hepatology 63, 1325-1339, doi:10.1002/hep.28112 (2016).
13. Ceccarelli, S. et al. LPS-induced TNF-alpha factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. Oncotarget 6, 41434-41452, doi:10.18632/oncotarget.5163 (2015).
14. Guijarro, C. & Egido, J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney international 59, 415-424, doi:10.1046/ j.1523-1755.2001.059002415.x (2001).
15. Klahr, S. & Morrissey, J. Obstructive nephropathy and renal fibrosis. American journal of physiology. Renal physiology 283, F861-875, doi:10.1152/ajprenal.00362.2001 (2002).
16. Oku, H., Nakazato, H., Horikawa, T., Tsuruta, Y. & Suzuki, R. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. European journal of pharmacology 446, 167-176 (2002).
17. Tian, S. et al. HMGB1 exacerbates renal tubulointerstitial fibrosis through facilitating M1 macrophage phenotype at the early stage of obstructive injury. American journal of physiology. Renal physiology 308, F69-75, doi:10.1152/ajprenal.00484.2014 (2015).
18. Inoue, K. et al. Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3. Laboratory investigation; a journal of technical methods and pathology 92, 1686-1697, doi:10.1038/labinvest.2012.107 (2012).
19. Komada, T. et al. ASC in renal collecting duct epithelial cells contributes to inflammation and injury after unilateral ureteral obstruction. The American journal of pathology 184, 1287-1298, doi:10.1016/j.ajpath.2014.01.014 (2014).
20. Sasaki, K. et al. Inhibition of SET Domain-Containing Lysine Methyltransferase 7/9 Ameliorates Renal Fibrosis. Journal of the American Society of Nephrology: JASN 27, 203-215, doi:10.1681/asn.2014090850 (2016).
21. Sun, Y. B. et al. Smad3 deficiency protects mice from obesity-induced podocyte injury that precedes insulin resistance. Kidney international 88, 286-298, doi:10.1038/ki.2015.121 (2015).
22. Lloyd, S., Bujkiewicz, S., Wailoo, A. J., Sutton, A. J. & Scott, D. The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology 49, 2313-2321, doi:10.1093/rheumatology/ keq169 (2010).
23. Valesini, G. et al. Biological and clinical effects of anti-TNFalpha treatment. Autoimmunity reviews 7, 35-41, doi:10.1016/j. autrev.2007.03.003 (2007).
24. Sugita, A. et al. Antiallergic and anti-inflammatory effects of a novel I kappaB kinase beta inhibitor, IMD-0354, in a mouse model of allergic inflammation. International archives of allergy and immunology 148, 186-198, doi:10.1159/000161579 (2009).
25. Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D. & Kossen, K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 20, 85-97, doi:10.1183/09059180.00001111 (2011).
26. Kaushik, N. K. et al. Biomedical importance of indoles. Molecules 18, 6620-6662, doi:10.3390/molecules18066620 (2013).
27. Nakada, K. et al. Inter-mitochondrial complementation: Mitochondria-specific system preventing mice from expression of disease phenotypes by mutant mtDNA. Nature medicine 7, 934-940, doi:10.1038/90976 (2001).